Inside Arbor’s CNS pipeline and next-generation gene editing
NOV 13, 202632 MIN
/https%3A%2F%2Fstorage.buzzsprout.com%2Fxgnf7feo4ae8beetwhl5m894pt15%3F.jpg)
Description
Gene editing has spent the last decade proving what's possible in the lab. The next decade is about proving it can reach the patients who need it most, from ultra-rare liver diseases to conditions like ALS, where no truly effective treatments exist today.
Arbor Biotechnologies is one of the companies pushing that frontier, built on a diverse toolbox of editing technologies that goes beyond the limitations of first-generation CRISPR tools. Its lead clinical program, ABO-101, targets PH1, and last October the company struck a partnership with Chiesi Group worth up to two billion dollars in milestones, with European regulators granting the program orphan drug designation just this summer.
Arbor is also building out a CNS pipeline focused initially on ALS. Here to talk through the science, the strategy, and what's next is Devyn Smith, CEO of Arbor Biotechnologies.
01:36 – Meet Devyn Smith
07:48 – Arbor's toolbox approach versus single-editor CRISPR companies
12:16 – What PH1 is and how ABO-101 works
15:19 – Inside the Chiesi partnership for ABO-101
20:14 – Why ALS anchors Arbor's CNS pipeline
26:48 – Arbor's three-year outlook and long-term vision
Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!
Stay updated by subscribing to our newsletter
To dive deeper into the topic:
What’s on the horizon for gene editing-based therapies?
CRISPR technology’s next wave: Ten companies to watch in 2025
Beyond CRISPR: What CAST could bring to genome editing


/https%3A%2F%2Fstorage.buzzsprout.com%2Fxgnf7feo4ae8beetwhl5m894pt15%3F.jpg)